NEOMED and IRICoR Join Forces to Facilitate the Discovery of Candidate Drugs for Unmet Medical Needs

NEOMED and the Institute for Research in Immunology and Cancer – Commercialisation of Research (IRICoR) have entered today into a strategic collaboration to accelerate the development and transfer of promising drug candidates between academia and the biopharmaceutical industry. The organisations will use their complementary strengths and capabilities in the value chain going from target identification to human proof-of-concept to deliver potential therapies for unmet medical needs. NEOMED and IRICoR will allow access to each other's state-of-the-art facilities, equipment, expertise and resources to advance jointly selected projects.

 

“With this partnership, we will leverage our respective strengths to build robust projects and deliver strong and high quality candidate drugs with potential to treat diseases in multiple therapy areas,” said Dr. Philippe Walker, Chief Scientific Officer of NEOMED. “IRICoR has established a very strong High Throughput Screening platform and medicinal chemistry expertise that is crucial to the hit identification and optimization stages of drug discovery”.

“We are very pleased to announce this key strategic partnership with IRICoR. We strongly believe in the power of collaborating to create an effective translational research environment. This partnership represents an important step toward NEOMED and NEOMED Institute global objectives to establish an open innovation hub fully integrated in the Canadian life sciences ecosystem,” said Dr. Max Fehlmann, President and Chief Executive Officer of NEOMED and the NEOMED Institute.

Dr. Michel Bouvier, President and Chief Executive Officer of IRICoR commented, “This strategic partnership will allow IRICoR to take advantage of the expertise and complementary research infrastructure of the NEOMED team and will allow us to advance our joint projects to the stage of human proof-of-concept. By working with NEOMED, IRICoR and our host institution, Université de Montréal, will be able to maximize the value of innovative Quebec discoveries”.

About NEOMED and the NEOMED Institute
NEOMED is a not-for-profit, public-private Pharma alliance dedicated to drug discovery and development, acting as a foster home for promising assets emerging from academia and biotechnology companies. NEOMED provides industry-level expertise and funding to bring emerging therapeutic approaches up to human proof-of-concept, a stage where the projects will become attractive to the biopharmaceutical industry. NEOMED is funded jointly by AstraZeneca, Pfizer and the Ministère des finances et de l'Économie du Québec.

NEOMED is established within the NEOMED Institute, a state-of-the-art R&D facility in the Montreal Technoparc. The Institute acts as an open-access drug discovery hub hosting commercial groups and providing a unique environment to foster innovation, collaboration and creativity.

For more information, please visit: www.neomed.ca

About IRICoR
IRICoR is a non-profit organization whose mandate is to accelerate the discovery, development and commercialization of novel drugs that originate from Université de Montréal. IRICoR, as a Center of Excellence in Commercialization and Research, invests in highly innovative projects to rapidly transition them from academia to the market, while identifying the best development partners for these commercially-promising projects.

For more information about IRICoR, please visit www.iricor.ca

For more information, please contact:

 

Mounia Azzi, PhD

Director, Scientific Affairs

NEOMED

514 909-7714

mazzi@neomed.ca

 
 

Steven Klein, PhD, MBA

Vice-President, Business Development

IRICoR

514 343-2116

steven.klein@iricor.ca